Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2012

01-08-2012 | SHORT REPORT

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples

Authors: Maria Grazia di Iasio, Riccardo Addobbati, Oriano Radillo, Rebecca Voltan

Published in: Investigational New Drugs | Issue 4/2012

Login to get access

Excerpt

Despite impressive improvements in response rates of chronic lymphocytic leukemia (CLL) patients using the combination of fludarabine, cyclophosphamide and rituximab, patients refractory to this combination or patients that have suffered multiple disease relapses have a poor outcome [1, 2]. In cells with functional p53, the p53 activity is primarily inhibited through direct and tonic interaction with the human homolog of the murine double minute 2 (MDM2) protein. The small molecule Nutlin-3 was originally described as a potent and selective inhibitor of the p53/MDM2 interaction [3], able to rise the levels of p53 protein and to induce cell cycle arrest and/or apoptosis in a variety of tumor cell lines [3] including hematological malignancies [4]. The p53 gene is deleted (17p-) and/or mutated in <15% of B-CLL patients at diagnosis and in >30% of B-CLL patients with pre-treated disease [5]. 17p- as well as monoallelic mutation of TP53 in the absence or presence of 17p- deletion has been associated with a poor prognosis [5]. …
Literature
1.
Wierda W, O’Brien S, Wen S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070–4078CrossRefPubMed
2.
Keating MJ, O’Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079–4088CrossRefPubMed
3.
4.
Secchiero P, di Iasio MG, Gonelli A, Zauli G (2008) The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Curr Pharm Des 14:2100–2110CrossRefPubMed
5.
Wattel E, Preudhomme C, Hecquet B et al (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148–3157PubMed
6.
Secchiero P, Barbarotto E, Tiribelli M et al (2006) Functional integrity of the p53 mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122–4129CrossRefPubMed
7.
Kojima K, Konopleva M, McQueen T et al (2006) Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993–1000CrossRefPubMed
8.
Saddler C, Ouillette P, Kujawski L et al (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:1584–1593CrossRefPubMed
9.
Secchiero P, Corallini F, Gonelli A et al (2007) Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61–69CrossRefPubMed
10.
Calin GA, Liu CG, Sevignani C et al (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101:11755–11760CrossRefPubMed
11.
Calin GA, Ferracin M, Cimmino A et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–1801CrossRefPubMed
12.
Dijkstra MK, van Lom K, Tielemans D et al (2009) 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 23:625–627CrossRefPubMed
13.
Mraz M, Malinova K, Kotaskova J et al (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23:1159–1163CrossRefPubMed
14.
Zenz T, Mohr J, Eldering E et al (2009) miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113:3801–3808CrossRefPubMed
15.
Zenz T, Habe S, Denzel T et al (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589–2597CrossRefPubMed
16.
Rossi S, Shimizu M, Barbarotto E et al (2010) microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116:945–952CrossRefPubMed
17.
Fabbri M, Bottoni A, Shimizu M et al (2011) Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305:59–67CrossRefPubMed
18.
Zauli G, Voltan R, di Iasio MG et al (2011) miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011 Mar 2. [Epub ahead of print]
19.
Wang M, Tan L, Dijkstra M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13–20CrossRefPubMed
20.
Li S, Moffett HF, Lu J et al (2011) MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS ONE 6:e16956CrossRefPubMed
21.
Secchiero P, Melloni E, di Iasio MG et al (2009) Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 113:4300–4308CrossRefPubMed
22.
Zauli G, Re MC, Furlini G, Giovannini M, La Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417–421CrossRefPubMed
23.
Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135CrossRefPubMed
24.
Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395–403CrossRefPubMed
25.
Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S (1996) Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 271:22961–22964CrossRefPubMed
26.
Secchiero P, Sun D, De Vico AL et al (1997) Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol 71:4571–4580PubMed
Metadata
Title
Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples
Authors
Maria Grazia di Iasio
Riccardo Addobbati
Oriano Radillo
Rebecca Voltan
Publication date
01-08-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9695-4

Other articles of this Issue 4/2012

Investigational New Drugs 4/2012 Go to the issue

PHASE II STUDIES

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

PRECLINICAL STUDIES

Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis

PHASE I STUDIES

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

PRECLINICAL STUDIES

Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells

PHASE I STUDIES

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

PHASE I STUDIES

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits